Skip to Main Content

Paper Details

TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline <i>BRCA</i> Carriers With HER2-Negative Breast Cancer (the INFORM trial).
J Clin Oncol
82
2020
Author NameAffiliation
Michele R HackerBeth Israel Deaconess Medical Center
Steven J IsakoffMassachusetts General Hospital
Claudine IsaacsLombardi Comprehensive Cancer Center
Antonio C WolffJohns Hopkins Kimmel Cancer Center
Paul K MarcomDuke Medical Center
Ian E KropDana-Farber Cancer Institute
Eric P WinerDana-Farber Cancer Institute
Judy E GarberDana-Farber Cancer Institute
  • 1 - 8

Datasets

Release 1.2